SERIES
CAR-T Series
Cell therapy at the frontier — entering the in vivo era
CAR-T cell therapy is a revolutionary treatment that genetically modifies a patient’s own T cells to attack cancer. The recent focus on “in vivo CAR-T” is accelerating the race to eliminate manufacturing bottlenecks. This series covers the front lines.
📋 Reading Path
- Basics: CAR-T Fundamentals and Current State
- ex vivo: Approved CAR-T Therapies
- in vivo 1–6: Complete Overview of in vivo CAR-T
- 2025 Race: Latest Updates
- Future: Next-Generation Cell Therapy
📚 All Articles in This Series
🔗 Related Series
Bispecific Antibody Series / ADC (Antibody-Drug Conjugate) Series / KRAS Deep Dive / Oncology Approval News
